July 2021

KBLP-007 phase 2a study approval (US)

June 2021

KBLP-007 phase 2a study IND filing (US)

March 2021

KBLP-002 phase 1 study completion

November 2020

Licensing agreement with Kolmar Korea Holdings

KOSDAQ stock market enlisted (IPO)

August 2020

US FDA IND Approval of KBLP-001 phase 2 study

May 2020

KBLP-001 phase 1 study completion

April 2020

KBLP-007 Non-IND human PoC study for ulcerative colitis initiated (KR)

KBLP-002 Non-IND human PoC study for asthma initiated (KR)

March 2020

KBLP-002 Phase 1 HREC approval (AU)

September 2019

KBLP-001 phase 1 study HREC approval (AU)

27b Pre-IPO funding completed

February 2019

Attracted ?4b strategic investment from CJ CheilJedang Co., Ltd.

December 2018

KBLF-001/KBLF-002 IRB approval of human study in Samsung Medical Center (KR)
(Non-IND human PoC study for atopic dermatitis)

November 2018

KBLF-003 IRB approval of human study in Samsung Medical Center (KR)
(Non-IND human PoC study for depression)

Established KoBioLabs Australia Pty Ltd.

May 2018

Received the Ministry of Science and ICT Award

Psychiatric program, selected as government sponsored project by MOTIE(Ministry of Trade, Industry and Energy)

July 2017

10b Series A funding closed

Atopic dermatitis program, selected as government sponsored project by MOTIE(Ministry of Trade, Industry and Energy)

Chronic kidney disease program, selected as government sponsored project by MSS(Ministry of SMEs and Startups)

July 2016

C. diffinfection program, selected as government sponsored project by MSIP(Ministry of Science, ICT and Future Planning)

March 2016

1.5b Pre-Series A funding closed

May 2015

Corp R&D institute established

November 2014

Certification of Venture Business

August 2014

Kobiolabs, Inc. founded, a spin-off from Microbiome Center at Seoul National University

KoBioLabs - Target Therapeutic Area Drug Pipeline

Products Details